Link Biologics is pioneering the development of protein biologics that harness the protective biology of TSG-6 and set new standards of care via multi-pathway modulation of inflammation, tissue protection and repair.
TSG-6 is an endogenous human protein known for its diverse tissue-protective and anti-inflammatory properties. It reduces inflammation through multiple mechanisms, limits tissue injury, and promotes rapid healing and repair without fibrosis. TSG-6 mediates many of the immunomodulatory and regenerative effects of human mesenchymal stem cells (MSCs). This latter discovery has generated extensive research into the therapeutic benefits of recombinant human full-length TSG-6 protein (rhTSG-6) across numerous models of inflammatory and degenerative diseases.
We are developing novel protein therapeutics targeting inflammatory and degenerative diseases. This includes our lead asset, Link_TSG6, the isolated Link module domain from human TSG-6, which underpins the LB001 and LB002 programme (see pipeline section).
Link_TSG6 (protein biologic)
Link_TSG6 (protein biologic)
The TSG-6 protein has an endogenous role to protect tissues from inflammatory damage and promote repair. Our TSG-6-based therapies have enhanced activities compared to the native protein. Unlike conventional therapies that block single pathways these biologics modulate multiple aspects of disease by combining anti-inflammatory, tissue-protective and tissue-reparative properties. Moreover, they do not act as a simple on/off switch but rather as a biological rheostat, fine-tuning intrinsic pathways to promote tissue repair and regulate inflammation.
With broad potential across inflammatory and degenerative conditions, our lead programmes focus on Dry Eye Disease (DED) and Wet Age-related Macular Degeneration (AMD); together these represent multi-billion-dollar global markets with significant unmet needs. (see pipeline section).
124 City Road, London, EC1V 2NX, U.K.
Registered in England and Wales. Registration no. 12550888